Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
51 studies found for:    "methodist hospital" | Open Studies | "Carcinoma" | United States, Texas | Houston
Show Display Options
Rank Status Study
1 Recruiting Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma
Conditions: Lung Squamous Cell Carcinoma Stage IV;   Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: nivolumab
2 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
3 Recruiting HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Conditions: Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
Interventions: Biological: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
4 Recruiting TAA-Specific CTLS for Solid Tumors (TACTASOM)
Conditions: Bladder Cancer;   Breast Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastric Cancer;   Head and Neck Cancer;   HCC;   Lung Cancer;   Melanoma;   Neuroblastoma;   Sarcoma (Osteo-, Synovial, Rhabdomyo-, Etc);   Pancreatic Cancer;   Prostate Cancer;   Renal Cell Carcinoma;   Thyroid Cancer
Intervention: Biological: TAA-Specific CTLs
5 Not yet recruiting SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Conditions: Metastatic Non-small Cell Lung Cancer;   Metastatic Triple-negative Breast Cancer
Interventions: Biological: ADV/HSV-tk;   Drug: Valacyclovir;   Radiation: SBRT;   Drug: Pembrolizumab
6 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
7 Recruiting Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis
Conditions: Breast Carcinoma Metastatic in the Brain;   Estrogen Receptor Negative;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Cognitive Assessment;   Drug: Palbociclib;   Procedure: Quality-of-Life Assessment;   Biological: Trastuzumab
8 Recruiting S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib
9 Recruiting S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
10 Recruiting A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Condition: Urothelial Carcinoma
Interventions: Drug: MOXR0916;   Drug: Atezolizumab;   Drug: Placebo
11 Recruiting Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cetuximab/Erbitux;   Drug: Cisplatin/Platinol;   Drug: Carboplatin/Paraplatin;   Drug: Fluorouracil/Adrucil
12 Recruiting Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
13 Recruiting Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
Condition: Localized Non-Resectable Adult Liver Carcinoma
Intervention: Other: Yttrium-90 Resin Microspheres
14 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy
15 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Condition: Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
16 Recruiting Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Other: Placebo
17 Recruiting Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: Dalantercept and axitinib;   Drug: Placebo and axitinib
18 Recruiting Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Condition: Advanced Cutaneous Squamous Cell Carcinoma
Intervention: Drug: REGN2810
19 Recruiting S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
20 Recruiting A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Condition: Carcinoma, Renal Cell
Interventions: Drug: tivozanib hydrochloride;   Drug: Sorafenib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.